December 2015- Volume 11, Issue 12

December 2015

In this Issue

Contract Services

Leaving the nest

Leaving the nest

Metrion completes management buyout from Xention

BioClinica launches eClinical CRO alliance program

BioClinica launches eClinical CRO alliance program

Access to eClinical knowledge, best practices and financial benefits aims to maximize CROs’ business and scientific success

Charles River announces new and continued drug discovery collaborations

Charles River announces new and continued drug discovery collaborations

Wellcome Trust-Funded projects expand partnerships with Charles River’s Global Discovery Services Business

Preclinical

IMO-2125 targets tumor microenvironment

IMO-2125 targets tumor microenvironment

Idera presents data demonstrating potent antitumor response from combo treatment with intratumoral IMO-2125

From candy to cancer

From candy to cancer

Calithera presents findings on potential cancer-inhibiting agent licensed from Mars Corp.

Model behavior

Model behavior

Crown announces alliance focused on translational models and hosts symposia to boost discussion

Discovery

New therapy for rheumatoid arthritis

New therapy for rheumatoid arthritis

Results of Compugen collaboration with Iain B. McInnes of Glasgow University presented at rheumatology meeting

Triggering stroke recovery

Triggering stroke recovery

UCLA researchers show role of GDF10 molecule in brain repair

Shedding some light on the ‘dark proteome’

Shedding some light on the ‘dark proteome’

St. Jude’s and TSRI join with others to explore proteins in the human proteome that don’t take standard 3D structures

Flying high with Kite and Alpine?

Flying high with Kite and Alpine?

Kite Pharma and Alpine Immune Sciences announce research collaboration and license agreement

Research & Development

Ultrasound delivery

Ultrasound delivery

Researchers at MIT and MGH enable ultra-rapid delivery of drugs to the GI tract using ultrasound waves

Building the next generation

Building the next generation

Parkinson’s Disease Foundation and American Parkinson Disease Association collaborate to cultivate future scientists

FPA008 fires things up for Five Prime

FPA008 fires things up for Five Prime

A recent deal with Bristol-Myers Squibb has a potential $1.74B price tag for Five Prime

All about the data

All about the data

Parkinson’s Institute and IO Informatics collaborate on integrated data environment

Putting two spins on oncology

Putting two spins on oncology

Two University of Maryland spin-offs pursue anticancer therapies

Business & Government Policy

AstraZeneca to acquire ZS Pharma for $2.7B

AstraZeneca to acquire ZS Pharma for $2.7B

Deal brings to AstraZeneca ZS-9, which could be a best-in-class treatment for hyperkalemia

Annexing AxioMx

Annexing AxioMx

Abcam acquires AxioMx, boosts antibody development capabilities

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Two bigs make a giant

Two bigs make a giant

The $160-billion deal to combine Pfizer and Allergan would create largest pharma in the world

Clinical Trials

Battling brachyury

Battling brachyury

Phase 1 study indicates safety and efficacy of Bavarian Nordic vaccine in advanced cancer patients

WCG Foundation launches to spur global clinical research

WCG Foundation launches to spur global clinical research

Nonprofit has been established in large part to strengthen protections for research participants

Matters of the heart

Matters of the heart

ICON partners with iCardiac on Early Precision QT program for safer drugs

NEJM reports on Phase 3 ANNEXA studies of andexanet alfa

NEJM reports on Phase 3 ANNEXA studies of andexanet alfa

Full data set from ANNEXA-R also presented in late-breaking clinical trial session at AHA Scientific Sessions 2015

Diagnostics

Pushing the personalized healthcare envelope

Pushing the personalized healthcare envelope

Human Longevity launches Health Nucleus to provide most complete picture ever of human health with genomics and more

One method to rule them all

One method to rule them all

XRGenomics and Affymetrix collaboration aims at better testing for age-related diseases

Rheonix rising

Rheonix rising

Ithaca, N.Y.-based Rheonix raises $28.6 million to expand commercialization efforts for its molecular diagnostic technology

Q&A

Q&A: GenVec and gene-based medicine

Q&A: GenVec and gene-based medicine

The challenge of delivering on the promise of delivering genes as therapeutics

Feature

SLAS2016 Show Preview: A focus on the cell

SLAS2016 Show Preview: A focus on the cell

5th Annual Conference and Exhibition of the Society for Laboratory Automation and Screening (SLAS) to meet in San Diego and has added a new track focused on cellular technologies

Editor's Focus

Looking back at 2015; walking boldly into 2016

Looking back at 2015; walking boldly into 2016

DDNews' chief editor and publishers assess the year gone by and give a preview of what's to come in the coming year

Commentary

Disruption interruption

Disruption interruption

Sometimes, big promises are made in pharma, biotech and the life sciences by corporations that want to succeed, but what if they aren't backed up?

Guest Commentary: An ethical imperative to use biosimulation in drug development

Guest Commentary: An ethical imperative to use biosimulation in drug development

By using biosimulation, pharmaceutical companies and regulatory agencies expedite bringing new, safer therapies to patients
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022